Acute Myeloid Leukemia or Myelodysplasic Syndrome Clinical Trial
Official title:
Pilot Study Immunomonitoring NK Cells in Patients With Myeloid Malignancies
This project is a framework for developing new therapeutic strategies for acute myeloid
leukemia(AML)based immunotherapy.
the role of NK cells was demonstrated in AML and especially GVL effect (graft versus
leukemia) during allogeneic transplantation in these patients. However, it has been shown
that the phenotype of NK cells and their cytotoxic functions were altered during this
malignancy. In addition, in these patients, impaired NK function is associated with relapse.
lenalidomide it would have a beneficial effect on NK cells of AML patients? Does it have a
role in leukemic cells in this malignancy? what is its effect on the production of
pro-inflammatory cytokines? In vitro data show an effect of lenalidomide on the phenotype of
NK cells from healthy donors and patients with LAM, and despite these phenotypic changes,
the cytotoxic capacity of NK is not altered.Lenalidomide also induces a significant increase
in the production of TNF-alpha (tumor necrosis factor) by NK.
It also seems to have an effect on leukemic blasts of AML. So, the investigators hope this
study confirm these results in vivo in peripheral blood cells in patients treated with
lenalidomide.
n/a
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label